

Integration of ceritinib and bevacizumab as a promising treatment strategy for brain metastases from ALK mutation-position non-small cell lung cancer: a case report

Yinxue Xia¹, Shuhe Lu¹, Weixi Shen², Tao Xin², Chengjuan Fan², Chong Teng², Xiaowei Song², and Yanju Lv²

¹Harbin Medical University

²Second Affiliated Hospital of Harbin Medical University

March 25, 2021

Abstract

Ceritinib shows efficacy in ALK+ NSCLC patients with BM. However, the disease will inevitably progress over time due to acquired resistance. We now report a case with BM from advanced lung adenocarcinoma with ALK mutations who exhibited a surprising and long-term response to treatment of ceritinib combined with bevacizumab.

Hosted file

Manuscript.pdf available at <https://authorea.com/users/404053/articles/515368-integration-of-ceritinib-and-bevacizumab-as-a-promising-treatment-strategy-for-brain-metastases-from-alk-mutation-position-non-small-cell-lung-cancer-a-case-report>



Figure 1

Figure 2

Figure 3




Figure 4(a,b)




Figure 5(a,b)




Figure 6(a,b)

